The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma-Reference-Cited by-同舟云学术

The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma

Published:2024-03-11 Issue:7 Volume:14 Page:1261-1265
ISSN:2042-6976
Container-title:International Forum of Allergy & Rhinology
language:en
Short-container-title:Int Forum Allergy Rhinol

Author:

Rathi Vinay K.¹^ORCID,Soler Zachary M.¹,Schlosser Rodney J.¹²,Workman Alan D.³^ORCID,Chapurin Nikita⁴,Rowan Nicholas R.⁵^ORCID,Dusetzina Stacie B.⁶⁷

Affiliation:

1. Division of Rhinology and Sinus Surgery Department of Otolaryngology–Head and Neck Surgery Medical University of South Carolina Charleston South Carolina USA

2. Department of Surgery Ralph H. Johnson VA Medical Center Charleston South Carolina USA

3. Division of Rhinology Department of Otolaryngology–Head & Neck Surgery University of Pennsylvania Philadelphia Pennsylvania USA

4. Department of Otolaryngology–Head & Neck Surgery University of Florida Gainesville Florida USA

5. Department of Otolaryngology–Head and Neck Surgery The Johns Hopkins University School of Medicine Baltimore Maryland USA

6. Department of Health Policy Vanderbilt University School of Medicine Nashville Tennessee USA

7. Vanderbilt‐Ingram Cancer Center Nashville Tennessee USA

Abstract

Key points

In 2021, Medicare spending on biologics was $926 million in Part B (FFS) and $1.3 billion in Part D (FFS/MA).

Between 2017 and 2021, annual Medicare spending on biologics increased by approximately 200%.

Between 2023 and 2025, Medicare Part D OOP costs for biologics will decrease by an estimated 50%–60%.

Funder

Commonwealth Fund

Arnold Ventures

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alr.23344

Reference14 articles.

1. Out‐of‐pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population

2. CubanskiJ NeumanT FreedM Explaining the prescription drug provisions in the Inflation Reduction Act. KFF. 2023. Accessed December 20 2023.https://www.kff.org/medicare/issue‐brief/explaining‐the‐prescription‐drug‐provisions‐in‐the‐inflation‐reduction‐act/

3. Trends in price, spending, and utilization of omalizumab among Medicare beneficiaries

4. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer

5. Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Burden of Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: Interplay Between Quality of Life and Economic Implications;The Journal of Allergy and Clinical Immunology: In Practice;2024-07

2. Spending, utilization, and coverage for chronic rhinosinusitis with nasal polyposis therapies among Medicare Advantage beneficiaries;International Forum of Allergy & Rhinology;2024-06-25